New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standi...(ented today were findings from a separat...),Health

Date:5/20/2008

ented today were findings from a separate retrospective analysis using the Human Capital Management Services Research Reference Database. Containing claims from large employers in the U.S. between January 1, 2001 and September 30, 2006 showed the effect of persistence with anti-TNF therapies on work-related absences for employees with IBD (Crohn's disease or UC). Work absences of 294,983 employees without IBD and 1,380 employees with IBD were analyzed. Employees with IBD and treated for less than 48 weeks with anti-TNF therapies had more total health-related absence days (22.5) than those with at least 48 weeks of anti-TNF therapies (10.3). This was true for sick leave days (4.8 vs. 2.3; P = 0.44) and short-term disability days (17.6 vs. 8.0; P = 0.67). Investigators concluded from the analysis that persistence with anti-TNF therapies is associated with a trend toward reduced work absence, including sick leave and short-term disability, and that these indirect costs should be taken into account when considering treatment options available to patients with IBD.

About ACT 1 and ACT 2

ACT 1 and ACT 2 were multicenter, Phase 3, randomized, double-blind, placebo-controlled clinical trials conducted to evaluate the safety and efficacy of REMICADE for the treatment of adult patients with moderately to severely active UC experiencing an inadequate response to conventional therapy. A total of 728 patients with active UC unresponsive to at least one standard therapy, including corticosteroids, other immunosuppressants, or 5-ASAs, were enrolled in ACT 1 (n=364) and ACT 2 (n=364). Patients in ACT 1 and ACT 2 had endoscopic evidence of moderately to severely active UC (total Mayo score of 6 to 12) and an endoscopy sub-score of at least 2. ACT 1 patients received treatment with placebo or REMICADE 5 mg/kg or REMICADE 10 mg/kg at weeks 0, 2 and 6 and then every eight weeks through week 46 and had the last evaluation at week 54. ACT 2 patients received treatment with
'/>"/>

SOURCE Centocor Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin